DPR, a fragment peptide of enterostatin (VPDPR) having hypocholesterolemic activity, was introduced into the three homologous sites, EPR, DYR, and DPI, in the soybean -conglycinin 0 subunit by site-directed mutagenesis. The modified -conglycinin was expressed in Escherichia coli and recovered in the soluble fraction. After purification on ion-exchange HPLC, the modified -conglycinin was digested by trypsin to release integrated DPR. The yield of DPR from 1 mole of the modified -conglycinin was 1.2 mole.
Enterostatin (VPDPR), which is released from the amino terminus of procolipase on its conversion to colipase, inhibits food intake in animals fed a high-fat diet. [1] [2] [3] [4] Recently, we found that VPDPR and its fragment peptide DPR had hypocholesterolemic effects after oral administration in mice fed a high cholesterol-cholic acid diet, with the effect of DPR being stronger than that of VPDPR. 5) In order to exploit this hypocholesterolemic effect of DPR, we incorporated the DPR sequence into three homologous sequences found in the 0 subunit of soybean -conglycinin, one of the major soybean storage proteins (Fig. 1) . 6, 7) On introducing bioactive peptides into soybean protein by site-directed mutagenasis, we have chosen homologous sites in order to minimize changes in conformation, physico-chemical properties, and productivity in soybean. [8] [9] [10] In this study, three sequences, EPR, DYR, and DPI, which are found at residues 140-142, 186-188, and 366-368 in the -conglycinin 0 subunit, respectively, were changed to DPR by site-directed mutagenesis of cDNA. Since all three sequences are preceded by Arg residues, their modification will render the DPR motif susceptible to release by trypsin.
E. coli HMS174(DE3) (Novagen) was used as the host. The expression plasmid used here was pEC 0 , in which the cDNA encoding the -conglycinin 0 subunit was subcloned into the expression vector pET21d(þ) (Novagen) between the NcoI and BamHI sites.
11) The expression plasmid pEC 0 was used as the template for site-directed mutagenesis. First, the EPR sequence was changed to DPR, then DPI was changed to DPR, and finally the DYR to DPR substitution was completed. Site-directed mutagenesis with synthetic oligonucleotide primers was done using a QuickChange Site-Directed Mutagenesis kit (Stratagene). Replacement of nucleotides in primers was designed as follows;
140 Glu ! Asp: GAA ! GAT;
368 Ile ! Arg: ATC ! CGC; 187 Tyr ! Pro: TAC ! CCC. The mutated DNA sequences were confirmed a DNA sequencer (Applied Biosystems, Model 310).
The expression plasmid pEC 0 , or the mutated pEC 0 encoding the DPR-introduced 0 subunit, was used to transform the E. coli host strain, HMS174(DE3), which was grown as 2.8 L Luria-Bertani (pH 7.0) cultures in the presence of 50 g/ml ampicillin at 37 C, and induced with 1 mM IPTG for 48 h at 20 C. The induced cells were harvested by centrifugation. Portions of the cells were boiled in SDS sample buffer (62.5 mM Tris base, 2% SDS, 10% glycerol, 0.2 M 2-mercaptoethanol), and analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) with 11% acrylamide gels. Both the wild-type and DPR-introduced 0 subunits accumulated in the cells at a level of 15% of total E. coli proteins (Fig. 2, lanes 1 and 5) . Immunoblot analysis showed that the wild-type and modified 0 subunits were recognized by anti-recombinant 0 subunit serum (data not shown). Recombinant wild-type and DPR-expressing 0 subunits were purified. Cells were resuspended in buffer A (35 mM sodium phosphate, pH 7.6, 0.2 M NaCl, 10 mM 2-mercaptoethanol, 1 mM EDTA, 0.1 mM p-amidinophenyl methanesulfonyl fluoride hydrochloride (APMSF), 3 g/ml leupeptin and 0.02% NaN 3 Þ in a volume of 7 ml per gram of cells (wet weight), and disrupted by sonication on ice. Insoluble material was separated from the soluble fraction by centrifugation, and dissolved in SDS sample buffer. Both the recombinant wild-type and modified proteins were mainly recovered in the soluble fraction (Fig. 2, lanes 2 and 6) . The expressed proteins were initially fractioned using ammonium sulfate (15-45% saturation). Precipitated proteins were collected by centrifugation, and resuspended in buffer B (35 mM sodium phosphate, pH 7.6, 0.28 M NaCl, 10 mM 2-mercaptoethanol, 1 mM EDTA, 0.1 mM APMSF, 3 g/ ml leupeptin, and 0.02% NaN 3 ). The suspension was dialyzed overnight against buffer C (35 mM sodium phosphate, pH 7.6, 0.1 M NaCl, 10 mM 2-mercaptoethanol, 1 mM EDTA, 0.1 mM APMSF, 3 g/ml leupeptin and 0.02% NaN 3 ). The dialysate was clarified by centrifugation, and the resulting protein solution was fractionated by anion-exchange high performance liquid chromatography (HPLC) on a HiLoad 26/10 Q Sepharose high performance column (Amersham Pharmacia Biotech) equilibrated with buffer C. The elution was done with a linear gradient of 0.1-0.6 M NaCl over a period of 250 min. Fractions containing the recombinant DPR-expressing 0 subunit were identified by SDS-PAGE. The purity of both wild-type and modified proteins exceeded 90% (Fig. 2, lanes 4 and 8) . Purified proteins were dialyzed against pure water and lyophilized. This resulted in 4.9 mg of the wild-type protein and 6.1 mg of the modified protein being obtained from 1 L of culture.
To determine whether DPR could be released effectively from the modified 0 subunit as was predicted, the subunit was digested with trypsin. The wild-type or modified proteins (5 mg/ml) were adjusted to pH 8.0 and digested with trypsin (E/S = 1/50 [W/W], TPCK treated, from bovine pancreas, Sigma) for 12 h at 37 C, with the reaction being stopped by boiling. To isolate the released DPR, the digest (0.4 ml) of the modified 0 subunit was fractionated by reverse-phase HPLC on an octadecyl silica (ODS) column (Cosmosil 5C18-AR-II, 4:6 Â 150 mm, Nacalai Tesque). The column was eluted with a linear gradient of acetonitrile (1%/min), containing 0.1% TFA at a flow rate of 1 ml/min. The fraction eluted at the same retention time as synthetic DPR was collected (Fig. 3) . It was confirmed using a 492 protein sequencer (Applied Biosystems) that the fraction was pure DPR. The overall yield of purified DPR was approximately 39%. Namely, 1.2 mole of DPR was obtained per one mole of the modified 0 subunit. On the other hand, DPR was not detected in the tryptic digest of the wild-type recombinant 0 subunit (data not shown). Thus, it is expected that DPR would be released in the intestine after ingestion of modified 0 subunits. In a previous study, we introduced the VPDPR sequence into the soybean proglycinin A 1a B 1b subunit by site-directed mutagenesis to potentiate hypocholesterolemic activity. 8) However, after expression in E. coli, this modified proglycinin A 1a B 1b subunit was recovered in the insoluble fraction. Here, the DPR-expressing 0 subunit was recovered in the soluble fraction, suggesting that it was folded normally. The site of the EPR sequence is situated at the end of the extension region, which is suggested to have a minor role in proper folding.
11) According to the crystal structure of thesubunit, it is predicted that the DYR sequence is situated at the AB loop in the N-terminal -barrel and that the DPI sequence is in the loop between the N-domain and C-domain. 12) These observations suggest that no significant change occurred in the overall conformation of the 0 subunit when the DPR sequences were introduced. In a previous study, 0.4 mole of VPDPR was recovered from one mole of the modified glycinin A 1a B 1b subunit containing one VPDPR sequence, after digestion with trypsin and chymotrypsin.
8) The yield of DPR from 1 mole of the modified -conglycinin 0 subunit containing three DPR sequences after trypsin digestion was 1.2 mole. DPR and VPDPR have hypocholesterolemic effects at a dose of 50 mg/kg and 100 mg/kg, respectively. 5) Taken together, these results suggest that the DPR-expressing -conglycinin 0 subunit is superior to the VPDPR-expressing glycinin A 1a B 1b subunit with respect to hypocholesterolemic activity. In this study, we introduced 3 DPR sequences by single amino acid replacement. We could introduce five additional DPR sequences into homologous sites by replacing single amino acid residues at the 12nd, 37th, 43rd, 81st, and 84th position in IPR, QPR, FPR, DER, and HPR sequences, respectively, in the extension region of the 0 subunit. However, these sites are not preceded by protease-sensitive residues. Therefore, another substitution of the preceding residues would be required to facilitate the release of DPR from these sites by proteases.
On the basis of the minimum effective dose of DPR required to mediate a hypocholesterolemic effect in mice, the amount of DPR released from the modified 0 subunit might not be sufficient for biological activity. Recently, we found that DPR stimulated the secretion of bile acids (unpublished observations). The -conglycinin 0 subunit was reported to activate LDL receptors in a human hepatoma cell line (Hep G2).
13) Furthermore, -conglycinin was found to have hypocholesterolemic activity in rats.
14) It will be interesting to find to what extent the hypocholesterolemic activity of -conglycinin in vivo is potentiated by this genetic modification. This will need to be tested after production of modifiedconglycinin in plants, since the yield in E.coli is too small for an in vivo study.
